BridgeMD
New treatment option for Multiple Myeloma
Official title Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
ClinicalTrials.gov ID: NCT05444348
What this study is testing
- What it's testing
- Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must:
- Be at least 18 years of age
- Have a diagnosis of one of the following:
- High-risk myelodysplastic syndrome (MDS) or MDS with overlap of myeloproliferative neoplasms (high-risk MDS/MPN),
- Acute myeloid leukemia(AML): Age≥80 or in palliative treatment or relapse
You likely can't join if
- Patient and caregiver are excluded if one of them is:
- \- Suffering from a severe psychiatric disorder
- Physicians and nurses:
- \- If they do not meet the inclusion criterion.
See the full eligibility criteria
- Patients must:
- Be at least 18 years of age
- Have a diagnosis of one of the following:
- High-risk myelodysplastic syndrome (MDS) or MDS with overlap of myeloproliferative neoplasms (high-risk MDS/MPN),
- Acute myeloid leukemia(AML): Age≥80 or in palliative treatment or relapse
- Lymphoma: Age≥80 or relapse or refractory or palliative treatment
- Multiple myeloma(MM): Age≥80 or relapsed or refractory Have limited treatment options. Provide informed consent. Have sufficient Danish skills to complete intervention sessions and data collection An informal caregiver...
- Be at least 18 years of age
- Be able to accompany patients to intervention appointments
- Provide informed consent
- Have sufficient Danish skills to complete intervention sessions and data collection Physicians:
- specialized in hematology
- treating patients with High risk myelodysplastic syndrome, acute myeloid leukemia, lymphoma, or multiple myeloma
- work at the same department for the entire time of intervention. Nurses:
- treating patients with High-risk myelodysplastic syndrome, acute myeloid leukemia, lymphoma, or multiple myeloma
- work at the same department for the entire time of intervention.
- Patient and caregiver are excluded if one of them is:
- \- Suffering from a severe psychiatric disorder
- Physicians and nurses:
- \- If they do not meet the inclusion criterion.
The study team makes the final eligibility decision.
Where it's taking place
- Aalborg, Denmark
- Aarhus, Denmark
- Esbjerg, Denmark
- Herning, Denmark
- Odense, Denmark
- Roskilde, Denmark
- Vejle, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aalborg, Denmark; Aarhus, Denmark; Esbjerg, Denmark; Herning, Denmark; Odense, Denmark; Roskilde, Denmark and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.